Login Register Cart 0
Mini-Review Article

接种或不接种； 就是那个问题！ （对 COVID-19 疫苗接种的新见解）

卷 22, 期 7, 2022

发表于: 11 May, 2021

页: [567 - 571] 页: 5

弟呕挨: 10.2174/1566524021666210512012315

价格: $65

Open Access Journals Promotions 2
摘要

目的：这篇文献综述旨在讨论在当前大流行时代接种疫苗的障碍和益处，无论是即将发布的 COVID-19 疫苗，还是流感疫苗，关于哪些争论正在研究它们对改善 COVID-19 大流行严重程度的有效性。 方法：在 PubMed 数据库中进行了文献检索，直到 2020 年 11 月。 结果：详细讨论了 COVID-19 疫苗接种背后的病理生理学、相关障碍和未来前景。还介绍了大流行期间流感疫苗接种的讨论以及最新的指南。 结论：在 COVID-19 大流行期间，只要没有禁忌症，所有个人都必须接种流感疫苗。到目前为止，三种 SARS-CoV-2 疫苗正在发布，而 FDA 正在批准单克隆抗体用于治疗高危门诊患者以降低住院率。

关键词: COVID-19、流感疫苗、SARS-CoV-2、COVID-19 疫苗、COVID-19 单克隆抗体、大流行。

« Previous Next »
[1]
Shahverdi M, Darvish M. Therapeutic measures for the novel coronavirus: A review of current status and future perspective. Curr Mol Med 2020; 21(7): 562-72.
[PMID: 33272178]
[2]
Coudeville L, Gomez GB, Jollivet O, et al. Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry. Vaccine 2020; 38(48): 7588-95.
[http://dx.doi.org/10.1016/j.vaccine.2020.10.034] [PMID: 33097312]
[3]
Ovais Ahmad Z, Rabia H, Rohina B, Mohammad Afzal Z. COVID-19 pandemic: current scenario, challenges and future perspectives. Coronaviruses 2020; 1: 1-17.
[4]
Ray SK, Mukherjee S. Understanding the role of corona virus based on current scientific evidence - a review with emerging importance in pandemic. Recent Pat Antiinfect Drug Discov 2020; 15(2): 89-103.
[http://dx.doi.org/10.2174/1574891X15999200918144833] [PMID: 32957894]
[5]
Subbarao K. COVID-19 vaccines: Time to talk about the uncertainties. Nature 2020; 586(7830): 475.
[http://dx.doi.org/10.1038/d41586-020-02944-8] [PMID: 33082537]
[6]
BioNTech PIa Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study all COVID-19 Updates 2020.
[7]
Jesus EGd Moderna says its COVID-19 vaccine is nearly 95 percent effective. Science News 2020.
[8]
Veer S, Vishal M. Coronavirus disease 2019 [COVID-19]: current situation and therapeutic options. Coronaviruses 2020; 1: 1-11.
[9]
Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397(10275): 671-81.
[http://dx.doi.org/10.1016/S0140-6736(21)00234-8] [PMID: 33545094]
[10]
Heaton PM. The covid-19 vaccine-development multiverse. N Engl J Med 2020; 383(20): 1986-8.
[http://dx.doi.org/10.1056/NEJMe2025111] [PMID: 32663910]
[11]
Odone A, Bucci D, Croci R, Riccò M, Affanni P, Signorelli C. Vaccine hesitancy in COVID-19 times. An update from Italy before flu season starts. Acta Biomed 2020; 91(3): e2020031.
[PMID: 32921733]
[12]
Laine C, Cotton D, Moyer DV. COVID-19 vaccine: What physicians need to know. Ann Intern Med 2020; 173(10): 830.
[http://dx.doi.org/10.7326/M20-6841] [PMID: 33074704]
[13]
Dutta AK. Vaccine against Covid-19 Disease - Present status of development. Indian J Pediatr 2020; 87(10): 810-6.
[http://dx.doi.org/10.1007/s12098-020-03475-w] [PMID: 32880819]
[14]
Mahase E. Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts. BMJ 2020; 371: m4042.
[http://dx.doi.org/10.1136/bmj.m4042] [PMID: 33093065]
[15]
Debisarun PA, Struycken P, Domínguez-Andrés J, et al. The effect of influenza vaccination on trained immunity: Impact on COVID-19. medRxiv 2020:2020.10.14.20212498.
[16]
Behrouzi B, Araujo Campoverde MV, Liang K, et al. Influenza vaccination to reduce cardiovascular morbidity and mortality in patients with COVID-19: JACC state-of-the-art review. J Am Coll Cardiol 2020; 76(15): 1777-94.
[http://dx.doi.org/10.1016/j.jacc.2020.08.028] [PMID: 33032740]
[17]
Wolff GG. Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season. Vaccine 2020; 38(2): 350-4.
[http://dx.doi.org/10.1016/j.vaccine.2019.10.005] [PMID: 31607599]
[18]
Paget J, Caini S, Cowling B, et al. The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. Vaccine 2020; 38(42): 6485-6.
[http://dx.doi.org/10.1016/j.vaccine.2020.08.024] [PMID: 32859436]
[19]
Wolff GG. Letter to the Editor. Vaccine 2020; 38(30): 4651.
[http://dx.doi.org/10.1016/j.vaccine.2020.04.016] [PMID: 32471778]
[20]
Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased influenza activity during the COVID-19 pandemic - united states, australia, chile, and south africa, 2020. MMWR Morb Mortal Wkly Rep 2020; 69(37): 1305-9.
[http://dx.doi.org/10.15585/mmwr.mm6937a6] [PMID: 32941415]
[21]
Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - united states, 2019-20 influenza season. MMWR Recomm Rep 2019; 68(3): 1-21.
[http://dx.doi.org/10.15585/mmwr.rr6803a1] [PMID: 31441906]
[22]
Wormser GP. COVID-19 versus seasonal influenza 2019-2020: USA. Wien Klin Wochenschr 2020; 132(13-14): 387-9.
[http://dx.doi.org/10.1007/s00508-020-01685-y] [PMID: 32514623]
[23]
Worldometer. COVID-19 Coronavirus Pandemic. Worldometer. 2020.
[24]
Härtl G. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. WHO announcements 2017.
[25]
Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science 2020; 370(6518): 763-5.
[http://dx.doi.org/10.1126/science.abe5938] [PMID: 33087460]
[26]
Soo RJJ, Chiew CJ, Ma S, Pung R, Lee V. Decreased influenza incidence under covid-19 control measures, Singapore. Emerg Infect Dis 2020; 26(8): 1933-5.
[http://dx.doi.org/10.3201/eid2608.201229] [PMID: 32339092]
[27]
Fierz W, Walz B. Antibody dependent enhancement due to original antigenic sin and the development of SARS. Front Immunol 2020; 11: 1120.
[http://dx.doi.org/10.3389/fimmu.2020.01120] [PMID: 32582200]
[28]
Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26(6): 845-8.
[http://dx.doi.org/10.1038/s41591-020-0897-1] [PMID: 32350462]
[29]
Bouvier NM, Palese P. The biology of influenza viruses 2008; 26(4): D49-53.
[http://dx.doi.org/10.1016/j.vaccine.2008.07.039]
[30]
Bouvin-Pley M, Morgand M, Meyer L, et al. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: A comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. J Virol 2014; 88(23): 13910-7.
[http://dx.doi.org/10.1128/JVI.02083-14] [PMID: 25231299]
[31]
Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools. Virol Sin 2020; 35(3): 266-71.
[http://dx.doi.org/10.1007/s12250-020-00207-4] [PMID: 32125642]
[32]
Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; 4(4): 4.
[http://dx.doi.org/10.1172/jci.insight.123158] [PMID: 30830861]
[33]
Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. Longitudinal monitoring of SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19. J Appl Lab Med 2020; 5(5): 908-20.
[http://dx.doi.org/10.1093/jalm/jfaa079] [PMID: 32428207]
[34]
Kohler H, Nara P. A novel hypothesis for original antigenic sin in the severe disease of SARS-CoV-2 infection. Monoclon Antib Immunodiagn Immunother 2020; 39(4): 107-11.
[http://dx.doi.org/10.1089/mab.2020.0029] [PMID: 32762609]
[35]
Tobin GJ, Trujillo JD, Bushnell RV, et al. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008; 26(49): 6189-99.
[http://dx.doi.org/10.1016/j.vaccine.2008.09.080] [PMID: 18852005]
[36]
Mahase E. Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients. BMJ 2020; 371: m4362.
[http://dx.doi.org/10.1136/bmj.m4362] [PMID: 33177042]
[37]
Mahase E. Covid-19: RECOVERY trial will evaluate “antiviral antibody cocktail”. BMJ 2020; 370: m3584.
[http://dx.doi.org/10.1136/bmj.m3584] [PMID: 32933902]
[38]
Yu W, Wu X, Ren J, et al. Mechanistic insights to the binding of antibody CR3022 against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A computational study. Comb Chem High Throughput Screen 2020; 23: 1-14.
[http://dx.doi.org/10.2174/1386207323666201026160500] [PMID: 33106140]
[39]
Rattanapisit K, Shanmugaraj B, Manopwisedjaroen S, et al. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana. Sci Rep 2020; 10(1): 17698.
[http://dx.doi.org/10.1038/s41598-020-74904-1] [PMID: 33077899]
[40]
Tavakol S, Alavijeh MS, Seifalian AM. COVID-19 vaccines on clinical trials and their mode of action for immunity against the virus. Curr Pharm Des 2020; 26: 1-11.
[http://dx.doi.org/10.2174/1381612826666201023143956] [PMID: 33100195]
[41]
Kulanthaivel S, Kaliberdenko VB, Balasundaram K, Shterenshis MV, Scarpellini E, Abenavoli L. Tocilizumab in Sars-cov-2 patients with the syndrome of cytokine storm; a narrative review. Rev Recent Clin Trials 2020; 15: 1-8.
[http://dx.doi.org/10.2174/1574887115666200917110954] [PMID: 32940187]
[42]
Ilias G, Georgia-Vasiliki G, Dimosthenis L, Kiriakos K, Sotiris T. The role of Interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19. Curr Med Chem 2021; 28: 1-10.

Rights & Permissions Print Cite
Article Metrics
52
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy